Zobrazeno 1 - 10 of 137 pro vyhledávání: '"Gourdin N"'
1
Akademický článek
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor.
Autor: Ducarouge B; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Redavid AR; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Victoor C; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Chira R; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Fonseca A; Research Pathology Department, Centre Léon Bérard, Lyon, France., Hervieu M; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Bergé R; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Lengrand J; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Vieugué P; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Neves D; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Goddard I; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Richaud M; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Laval PA; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Rama N; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Goldschneider D; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Paradisi A; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Gourdin N; Targeting of the Tumor and its Immune Environnement, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Chabaud S; UBET, Centre Léon Bérard, Lyon, France., Treilleux I; UBET, Centre Léon Bérard, Lyon, France., Gadot N; Pathology Department, Centre Léon Bérard, Lyon, France., Ray-Coquard I; Pathology Department, Centre Léon Bérard, Lyon, France., Depil S; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Decaudin D; Laboratory of Preclinical Investigations, Translational Research Department, Institut Curie, Université Paris-Sciences-et-Lettres, 75005, Paris, France., Némati F; Laboratory of Preclinical Investigations, Translational Research Department, Institut Curie, Université Paris-Sciences-et-Lettres, 75005, Paris, France., Marangoni E; Laboratory of Preclinical Investigations, Translational Research Department, Institut Curie, Université Paris-Sciences-et-Lettres, 75005, Paris, France., Mery-Lamarche E; Department of Pathology, IUCT Oncopole, Toulouse, France., Génestie C; Department of Pathology, Gustave Roussy, Villejuif, France., Tabone-Eglinger S; Pathology Department, Centre Léon Bérard, Lyon, France., Devouassoux-Shisheboran M; Department of Pathology, Hospices Civils de Lyon, 69002, Lyon, France., Moore KJ; Department of Medicine, Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY, USA., Gibert B; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France. benjamin.gibert@lyon.unicancer.fr., Mehlen P; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France. patrick.mehlen@lyon.unicancer.fr.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France. patrick.mehlen@lyon.unicancer.fr., Bernet A; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France. agnes.bernet@lyon.unicancer.fr.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France. agnes.bernet@lyon.unicancer.fr.
Publikováno v: Cell death and differentiation [Cell Death Differ] 2023 Oct; Vol. 30 (10), pp. 2201-2212. Date of Electronic Publication: 2023 Aug 26.
Zobrazit plný text záznamu
2
Akademický článek
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Autor: Gauthier L; Innate Pharma, Marseille, France. laurent.gauthier@innate-pharma.fr., Virone-Oddos A; Sanofi Immuno-Oncology Research, Vitry sur-Seine, France. Angela.Virone-Oddos@sanofi.com., Beninga J; Sanofi Large Molecules Research, Frankfurt, Germany., Rossi B; Innate Pharma, Marseille, France., Nicolazzi C; Sanofi Immuno-Oncology Research, Vitry sur-Seine, France., Amara C; Sanofi Drug Metabolism and Pharmacokinetics, Chilly Mazarin, France., Blanchard-Alvarez A; Innate Pharma, Marseille, France., Gourdin N; Innate Pharma, Marseille, France., Courta J; Sanofi TMED Biomarkers and Clinical Bioanalysis, Chilly Mazarin, France., Basset A; Sanofi Preclinical Safety, Chilly Mazarin, France., Agnel M; Sanofi Global Project Management, Vitry sur-Seine, France., Guillot F; Innate Pharma, Marseille, France., Grondin G; Innate Pharma, Marseille, France., Bonnevaux H; Sanofi Immuno-Oncology Research, Vitry sur-Seine, France., Bauchet AL; Sanofi Global Project Management, Vitry sur-Seine, France., Morel A; Innate Pharma, Marseille, France., Morel Y; Innate Pharma, Marseille, France., Chiron M; Sanofi Immuno-Oncology Research, Vitry sur-Seine, France., Vivier E; Innate Pharma, Marseille, France. eric.vivier@innate-pharma.fr.; Aix-Marseille University, Centre of National Scientific Research (CNRS), National Insititute of Health and Medical Research (INSERM), Centre of Immunology at Marseille-Luminy (CIML), Marseille, France. eric.vivier@innate-pharma.fr.; APHM, Marseille-Immunopole, University Hospital of Timone, Marseille, France. eric.vivier@innate-pharma.fr.
Publikováno v: Nature biotechnology [Nat Biotechnol] 2023 Sep; Vol. 41 (9), pp. 1296-1306. Date of Electronic Publication: 2023 Jan 12.
Zobrazit plný text záznamu
3
Akademický článek
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.
Autor: Demaria O; Innate Pharma, Marseille, France. Electronic address: olivier.demaria@innate-pharma.fr., Gauthier L; Innate Pharma, Marseille, France., Vetizou M; Innate Pharma, Marseille, France., Blanchard Alvarez A; Innate Pharma, Marseille, France., Vagne C; Innate Pharma, Marseille, France., Habif G; Innate Pharma, Marseille, France., Batista L; Innate Pharma, Marseille, France., Baron W; Innate Pharma, Marseille, France., Belaïd N; Innate Pharma, Marseille, France., Girard-Madoux M; Innate Pharma, Marseille, France., Cesari C; Innate Pharma, Marseille, France., Caratini M; Innate Pharma, Marseille, France., Bosco F; Innate Pharma, Marseille, France., Benac O; Innate Pharma, Marseille, France., Lopez J; Innate Pharma, Marseille, France., Fenis A; Innate Pharma, Marseille, France., Galluso J; Innate Pharma, Marseille, France., Trichard S; Innate Pharma, Marseille, France., Carrette B; Innate Pharma, Marseille, France., Carrette F; Innate Pharma, Marseille, France., Maguer A; Innate Pharma, Marseille, France., Jaubert S; Innate Pharma, Marseille, France., Sansaloni A; Innate Pharma, Marseille, France., Letay-Drouet R; Innate Pharma, Marseille, France., Kosthowa C; Innate Pharma, Marseille, France., Lovera N; Innate Pharma, Marseille, France., Dujardin A; Innate Pharma, Marseille, France., Chanuc F; Innate Pharma, Marseille, France., Le Van M; Innate Pharma, Marseille, France., Bokobza S; Innate Pharma, Marseille, France., Jarmuzynski N; Innate Pharma, Marseille, France., Fos C; Innate Pharma, Marseille, France., Gourdin N; Innate Pharma, Marseille, France., Remark R; Innate Pharma, Marseille, France., Lechevallier E; Assistance Publique des Hôpitaux de Marseille, Chirurgie Urologique et Transplantation Rénale, Hôpital de la Conception, Marseille, France., Fakhry N; Assistance Publique des Hôpitaux de Marseille, ORL et Chirurgie Cervico-Faciale, Hôpital de la Conception, Marseille, France., Salas S; Assistance Publique des Hôpitaux de Marseille, Service d'Oncologie Médicale et de Soins Palliatifs, CHU Timone Adulte, Marseille, France., Deville JL; Assistance Publique des Hôpitaux de Marseille, Oncologie Médicale, Hôpital de la Timone, Marseille, France., Le Grand R; Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Bonnafous C; Innate Pharma, Marseille, France., Vollmy L; Innate Pharma, Marseille, France., Represa A; Innate Pharma, Marseille, France., Carpentier S; Innate Pharma, Marseille, France., Rossi B; Innate Pharma, Marseille, France., Morel A; Innate Pharma, Marseille, France., Cornen S; Innate Pharma, Marseille, France., Perrot I; Innate Pharma, Marseille, France., Morel Y; Innate Pharma, Marseille, France., Vivier E; Innate Pharma, Marseille, France; Aix Marseille University, CNRS, INSERM, CIML, Marseille, France; Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Marseille-Immunopôle, Marseille, France. Electronic address: vivier@ciml.univ-mrs.fr.
Publikováno v: Cell reports. Medicine [Cell Rep Med] 2022 Oct 18; Vol. 3 (10), pp. 100783.
Zobrazit plný text záznamu
4
Akademický článek
CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer.
Autor: Magagna I; Equipe labellisée Ligue Nationale Contre le Cancer, Stress and Cancer Laboratory, Institut Curie, PSL Research University, 26, rue d'Ulm, 75005 Paris, France.; Inserm, U830, 75005 Paris, France.; Innate Pharma, 117 Avenue de Luminy BP 30191, 13276 Marseille, France., Gourdin N; Innate Pharma, 117 Avenue de Luminy BP 30191, 13276 Marseille, France., Kieffer Y; Equipe labellisée Ligue Nationale Contre le Cancer, Stress and Cancer Laboratory, Institut Curie, PSL Research University, 26, rue d'Ulm, 75005 Paris, France.; Inserm, U830, 75005 Paris, France., Licaj M; Equipe labellisée Ligue Nationale Contre le Cancer, Stress and Cancer Laboratory, Institut Curie, PSL Research University, 26, rue d'Ulm, 75005 Paris, France.; Inserm, U830, 75005 Paris, France., Mhaidly R; Equipe labellisée Ligue Nationale Contre le Cancer, Stress and Cancer Laboratory, Institut Curie, PSL Research University, 26, rue d'Ulm, 75005 Paris, France.; Inserm, U830, 75005 Paris, France., Andre P; Innate Pharma, 117 Avenue de Luminy BP 30191, 13276 Marseille, France., Morel A; Innate Pharma, 117 Avenue de Luminy BP 30191, 13276 Marseille, France., Vincent-Salomon A; Hospital Group, Department of Diagnostic and Theranostic Medicine, Institut Curie, 75005 Paris, France., Paturel C; Innate Pharma, 117 Avenue de Luminy BP 30191, 13276 Marseille, France., Mechta-Grigoriou F; Equipe labellisée Ligue Nationale Contre le Cancer, Stress and Cancer Laboratory, Institut Curie, PSL Research University, 26, rue d'Ulm, 75005 Paris, France.; Inserm, U830, 75005 Paris, France.
Publikováno v: Cancers [Cancers (Basel)] 2021 Nov 23; Vol. 13 (23). Date of Electronic Publication: 2021 Nov 23.
Zobrazit plný text záznamu
5
Akademický článek
Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells.
Autor: Testa, Ugo1 (AUTHOR) germana.castelli@iss.it, Castelli, Germana1 (AUTHOR), Pelosi, Elvira1 (AUTHOR)
Publikováno v: Cancers. Nov2024, Vol. 16 Issue 21, p3627. 29p.
Zobrazit plný text záznamu
6
Le bail rural à clauses environnementales : synthèse
Autor: Bertrand, N., Doussan, I., Gourdin, N.
La fiche consacrée aux BRE signés en Rhône-Alpes et Auvergne précise les conditions d'application de ces baux et l'outil qu'il représente pour les collectivités locales pour mettre en oeuvre une politique environnementale locale et décentralis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______166::a050be8faded13fe5fd7368976c886fd
https://hal.inrae.fr/hal-02604623
Zobrazit plný text záznamu
7
Akademický článek
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Autor: Perrot I; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Michaud HA; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, 34298 Montpellier, France., Giraudon-Paoli M; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Augier S; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Docquier A; OREGA Biotech, 69130 Ecully, France., Gros L; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, 34298 Montpellier, France., Courtois R; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Déjou C; OREGA Biotech, 69130 Ecully, France., Jecko D; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Becquart O; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, 34298 Montpellier, France; Département de Dermatologie, Centre Hospitalier Régional Universitaire de Montpellier et Faculté de Médecine, Université de Montpellier, 34295 Montpellier, France., Rispaud-Blanc H; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Gauthier L; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Rossi B; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Chanteux S; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Gourdin N; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Amigues B; CNRS, Aix Marseille Université, AFMB, Architecture et Fonction des Macromolécules Biologiques, 13009 Marseille, France., Roussel A; CNRS, Aix Marseille Université, AFMB, Architecture et Fonction des Macromolécules Biologiques, 13009 Marseille, France., Bensussan A; Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-S 976, Université Paris Diderot, Sorbonne Paris Cité, Laboratory of Human Immunology, Pathophysiology and Immunotherapy, 75475 Paris, France., Eliaou JF; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, 34298 Montpellier, France; Département d'Immunologie, Centre Hospitalier Régional Universitaire de Montpellier et Faculté de Médecine, Université de Montpellier, 34295 Montpellier, France., Bastid J; OREGA Biotech, 69130 Ecully, France., Romagné F; MI-mAbs, Aix Marseille Université, 117 Avenue de Luminy, 13009 Marseille, France., Morel Y; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France., Narni-Mancinelli E; Aix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France., Vivier E; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France; Aix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France; Service d'Immunologie, Marseille Immunopôle, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: vivier@ciml.univ-mrs.fr., Paturel C; Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France. Electronic address: carine.paturel@innate-pharma.fr., Bonnefoy N; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, 34298 Montpellier, France. Electronic address: nathalie.bonnefoy@inserm.fr.
Publikováno v: Cell reports [Cell Rep] 2019 May 21; Vol. 27 (8), pp. 2411-2425.e9.
Zobrazit plný text záznamu
8
Akademický článek
Autocrine Adenosine Regulates Tumor Polyfunctional CD73 + CD4 + Effector T Cells Devoid of Immune Checkpoints.
Autor: Gourdin N; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France.; Innovation and Translational Research Department, Centre Léon Bérard, Lyon, France., Bossennec M; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France., Rodriguez C; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France.; Innovation and Translational Research Department, Centre Léon Bérard, Lyon, France., Vigano S; Ludwig Cancer Research Center, Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland., Machon C; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Laboratoire de Biochimie et Toxicologie, Pierre-Bénite, France.; Université de Lyon, Université Lyon 1, ISPB Faculté de pharmacie, Laboratoire de Chimie Analytique, Lyon, France., Jandus C; Ludwig Cancer Research Center, Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland., Bauché D; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France.; TGF-β and Immuno-evasion Department of Immunology Virology and Inflammation, INSERM U1052, Cancer Research Center of Lyon, Lyon, France.; TGF-β and Immuno-evasion, Tumor immunology Program, DKFZ, Heidelberg, Germany., Faget J; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France.; Innovation and Translational Research Department, Centre Léon Bérard, Lyon, France., Durand I; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France.; Cytometry platform, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France., Chopin N; Centre Léon Bérard, Medical Oncology Department, Lyon, France., Tredan O; Centre Léon Bérard, Medical Oncology Department, Lyon, France., Marie JC; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France.; TGF-β and Immuno-evasion Department of Immunology Virology and Inflammation, INSERM U1052, Cancer Research Center of Lyon, Lyon, France.; TGF-β and Immuno-evasion, Tumor immunology Program, DKFZ, Heidelberg, Germany., Dubois B; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France., Guitton J; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Laboratoire de Biochimie et Toxicologie, Pierre-Bénite, France.; Université de Lyon, Université Lyon 1, ISPB Faculté de pharmacie, Laboratoire de Toxicologie, Lyon, France., Romero P; Ludwig Cancer Research Center, Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland., Caux C; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France.; Innovation and Translational Research Department, Centre Léon Bérard, Lyon, France., Ménétrier-Caux C; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France. christine.caux@lyon.unicancer.fr.; Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052, Cancer Research Center of Lyon, Lyon, France.; Innovation and Translational Research Department, Centre Léon Bérard, Lyon, France.
Publikováno v: Cancer research [Cancer Res] 2018 Jul 01; Vol. 78 (13), pp. 3604-3618. Date of Electronic Publication: 2018 Mar 20.
Zobrazit plný text záznamu
9
Akademický článek
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
Autor: Lin, Cindy Hsin-Ti1 (AUTHOR) hlin@metrohealth.org, Tariq, Muhammad Junaid2 (AUTHOR) muhammad.tariq@rosewellpark.org, Ullah, Fauzia3 (AUTHOR) ullahf@ccf.org, Sannareddy, Aishwarya4 (AUTHOR) aishwarya.sannareddy@utsouthwestern.edu, Khalid, Farhan5 (AUTHOR) farhankhalid17@gmail.com, Abbas, Hasan6 (AUTHOR) habbas@mcw.edu, Bader, Abbas7 (AUTHOR) abbasbader@mail.umkc.edu, Samaras, Christy3 (AUTHOR) samarac@ccf.org, Valent, Jason3 (AUTHOR) valentj3@ccf.org, Khouri, Jack3 (AUTHOR) khourij@ccf.org, Anwer, Faiz3 (AUTHOR) anwerf@ccf.org, Raza, Shahzad3 (AUTHOR) razas@ccf.org, Dima, Danai3,8 (AUTHOR) dimad@ccf.org
Publikováno v: International Journal of Molecular Sciences. Jun2024, Vol. 25 Issue 11, p6192. 23p.
Zobrazit plný text záznamu
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje